Peptide Encyclopedia / BPC-157 + TB-500
EncyclopediaBPC-157 + TB-500 pairs a synthetic gastric-derived pentadecapeptide with a thymosin beta-4 fragment, both promoted to drive blood vessel growth and tissue repair. Support comes mostly from animal and lab work, human data is sparse, and neither is FDA-approved or off WADA's banned list. Educational, not medical advice.
| Category | Healing / Recovery |
| Regulatory status | Not FDA-approved, individually or as a blend. |
A popular research-peptide pairing of BPC-157 (a synthetic pentadecapeptide derived from a gastric protein) and TB-500 (a synthetic fragment related to thymosin beta-4), both proposed to promote angiogenesis, cell migration, and tissue repair. Mechanisms are largely preclinical and not firmly established in humans.
uncertain; limited rigorous human PK for either peptide (both reported to be relatively short-lived). Commonly reported use/dosing: No approved protocol. Reported anecdotal use is subcutaneous injection of each peptide, often in microgram-to-milligram ranges over cycles; not clinically validated.
Not FDA-approved, individually or as a blend. BPC-157 is not an approved drug (FDA has flagged it among substances not meeting compounding criteria) and TB-500/thymosin beta-4 is unapproved; both are on WADA's prohibited list. Gray-market research-chemical status.
Human safety data limited; theoretical concerns include effects on angiogenesis (relevant to tumor growth) and unknown long-term effects. Research-grade products carry sterility/purity risk. Prohibited in sport.
Mostly animal/in-vitro research; sparse controlled human data. Not clinically validated as a combination.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. BPC-157 + TB-500 may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
